Johnson & Johnson has agreed to a $5.5 billion settlement to resolve about 76,000 lawsuits alleging its talc products caused ovarian cancer. The settlement aims to conclude a decade-long legal battle and requires participation from plaintiff firms representing at least 95% of remaining claims. The company will make an initial payment of up to $3 billion in 2027, with no further payments before 2028. Johnson & Johnson maintains its talc products are safe and welcomed a court ruling supporting its position after plaintiffs withdrew key expert testimony. This resolution allows the company to focus on its core healthcare mission while ending most talc-related litigation.
The FDA has granted Priority Review to Johnson & Johnson's subcutaneous amivantamab for treating adults with recurrent or metastatic head and neck squamous cell carcinoma after progression on chemotherapy and immunotherapy. This drug uniquely targets...
In 2026, the ProShares Dividend Aristocrat ETF (NOBL) has outperformed the S&P 500 ETF (SPY), delivering a 12.9% return compared to SPY's 7.88%. Dividend Aristocrats, known for consistent dividend growth, averaged a 4.10% increase this year, with not...
Investors are rotating out of AI infrastructure stocks such as Micron and Western Digital, which surged earlier this year due to memory shortages but have recently declined. CNBC's Jim Cramer highlights a shift toward companies with broader growth dr...
Johnson & Johnson announced a $5.5 billion settlement to resolve about 76,000 lawsuits alleging its talc-based baby powder caused ovarian cancer. The settlement covers federal and state claims but requires approval from 95% of claimants to finalize. ...
Johnson & Johnson has reached a historic $5.5 billion settlement to resolve claims from about 70,000 women and families alleging its talc products, including Johnson's Baby Powder, contained asbestos and caused cancers such as ovarian cancer and meso...
